Zytiga Sales Exceed Provenge

The approval of Johnson & Johnson's (JNJ) drug, Zytiga, earlier in 2011, is a drug which many felt would prove to be a formidable product. Indeed, sales of Zytiga already exceed those of Provenge. Zytiga works by blocking the production of androgens, like testosterone, on which many prostate tumors are dependent.